Abstract 11946: Effect of Evolocumab on Non-high-density Lipoprotein Cholesterol and Apolipoprotein B Levels: An Analysis of Double-blind and Open-label Extension Studies

Introduction: Dyslipidemia guidelines have recommended non-HDL-C and ApoB either as co-primary or secondary targets of therapy. Objective: To evaluate the effect of evolocumab on non-HDL-C and ApoB...